NCT04810507View on ClinicalTrials.gov

MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL

Enrollment

89

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

September 2, 2020

Study Completion Date

January 5, 2021

Conditions

Type 2 Diabetes

Interventions

DRUG

Anagliptin BID Treatment

Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks

Trial Locations (1)

Unknown

Kangdong Sacred Heart Hospital, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical

All Listed Sponsors

lead

JW Pharmaceutical

INDUSTRY

NCT04810507 - MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter